T-1105

• UNSPSC Description:

  T-1105, a structural analogue of T-705, is a novel broad-spectrum viral polymerase inhibitor. T-1105 inhibits the polymerases of RNA viruses after being converted to ribonucleoside triphosphate (RTP) metabolite. T-1105 has antiviral activity against various RNA viruses. T-1105 can be formed by nicotinamide mononucleotide adenylyltransferase[1][2].

• Target Antigen:

  Flavivirus

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/t-1105.html

• Purity:

  99.74

• Solubility:

  DMSO : 12.5 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C(C1=NC=CN=C1O)N

• Molecular Weight:

  139.114

• References & Citations:

  [1]Huchting J, et al. Cell line-dependent activation and antiviral activity of T-1105, the non-fluorinated analogue of T-705 (favipiravir). Antiviral Res. 2019 Jul;167:1-5.|[2]Furuta Y, et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009 Jun;82(3):95-102.|[3]Johanna Huchting, et al. Cell line-dependent activation and antiviral activity of T-1105, the non-fluorinated analogue of T-705 (favipiravir). Antiviral Res. 2019 Jul;167:1-5.|[4]Lei Cai, et al. Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication. Arch Virol. 2017 Sep;162(9):2847-2853. |[5]Hideki Tani, et al. Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus.|[6]Yousuke Furuta, et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009 Jun;82(3):95-102.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  55321-99-8